Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.35 |
| ▸ | ATG7 | O95352 | 1/20 | 0.35 |
| ▸ | UBA7 | P41226 | 1/20 | 0.35 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.35 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.35 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12567156 | 0.89 | CYP1A2 (0.45) | BCHEUBA6ATG7UBA7NAE1 | |
| SCHEMBL18630417 | 0.86 | ATG7 (0.45) | ATG7 | |
| SCHEMBL20008404 | 0.85 | NAE1 (0.42) | BCHEALDH1A1LMNAALBMAPK1 | |
| SCHEMBL18630415 | 0.83 | BCHE (0.43) | BCHEUBA6ATG7UBA7NAE1 | |
| SCHEMBL1798164 | 0.82 | TRPM2 (0.51) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL18630443 | 0.77 | BCHE (0.38) | BCHEALDH1A1LMNAALBMAPK1 | |
| SCHEMBL13773372 | 0.76 | BCHE (0.54) | BCHEALDH1A1LMNAALBMAPK1 | |
| SCHEMBL12652607 | 0.75 | NR2F2 (0.54) | ALDH1A1 | |
| SCHEMBL12652414 | 0.75 | UBA6 (0.47) | BCHEUBA6ATG7UBA7NAE1 | |
| SCHEMBL12567150 | 0.75 | BCHE (0.47) | BCHEALDH1A1LMNAALBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | BCHE 24/4885ALDH1A1 987/4885LMNA 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.